Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline
New Hemophilia Partners Also Circling
Low on cash when Pfizer handed back rights to its hemophilia A gene therapy, Sangamo is talking to partners for its Fabry disease gene therapy to fund its two lead programs through proof-of-concept.
